Close

Intellia Therapeutics (NTLA) Prices Public Offering of Common Stock at $45.80 Per Share

December 1, 2022 7:30 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share. Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Intellia.

Goldman Sachs & Co. LLC is the sole underwriter for the offering. The offering is expected to close on or about December 2, 2022, subject to customary closing conditions.

The shares of common stock are being offered by Intellia pursuant to an effective shelf registration statement, including a prospectus, that was previously filed with the U.S. Securities and Exchange Commission (SEC). The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from: Goldman Sachs & Co. LLC, by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Equity Offerings

Related Entities

Goldman Sachs